Cade approves pharmaceutical joint venture
Published in January 29, 2016
The Administrative Council for Economic Defense (Cade) approved without restrictions a joint venture between Pfizer and Orygen Biotecnologia, controlled by Biolab and Eurofarma, according to an order published in the Federal Official Gazette (DOU).
The joint venture will operate in the manufacture and marketing in Brazil of up to five biosimilars based on adalimumab, bevacizumab, infliximab, rituximab or trastuzumab. According to the companies, the operation represents the reformulation of a cooperation agreement signed in May 2014, approved by Cade in the same year. Orygen Biotecnologia is a joint venture between the Biolab and Eurofarma economic groups.